市場調査レポート
商品コード
1069315
放射線皮膚炎:世界市場の展望(2021年~2028年)Radiodermatitis - Global Market Outlook (2021-2028) |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
放射線皮膚炎:世界市場の展望(2021年~2028年) |
出版日: 2022年04月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
世界の放射線皮膚炎の市場規模は、2021年の5億757万米ドルから、2028年までに7億6,824万米ドルに達し、予測期間中に6.1%のCAGRで成長が予測されています。
当レポートでは、世界の放射線皮膚炎市場について調査分析し、市場動向分析、セグメント別・地域別の市場情報、企業プロファイルなどを提供しています。
According to Stratistics MRC, the Global Radiodermatitis Market is accounted for $507.57 million in 2021 and is expected to reach $768.24 million by 2028 growing at a CAGR of 6.1% during the forecast period. Radiodermatitis is the skin condition observed in the individuals undergoing radiation therapy used for the cancer treatment or certain skin disorders. The general symptoms associated with radiation burns include itching, redness, flaking, peeling, soreness, blisters, and others. Cumulative daily doses of radiation to the treatment field or target site on the body inhibits normal skin repopulation and fades skin integrity at and around the radiation field.
Market Dynamics:
Driver:
Increasing Prevalence of Cancer
The rate of certain types of cancers such as breast cancer and head and neck cancer is projected to rise. This is attributable to faulty lifestyle factors such as obesity for breast cancer, and smoking for head and neck cancers. These kinds of cancers are treated with radiation at site. So, patients suffering from these cancers are more likely to develop radiation-induced dermatitis. Therefore, the overall spiral in cancer cases coupled with a surge in specific cancers due to faulty lifestyle is likely to propel the radiodermatitis market.
Restraint:
Higher Radiodermatitis Cost
High cost radiodermatitis products may negatively impact the radiodermatitis market, in the coming years. The burden of cost of cancer treatment is a concern in developing nations, where high cost of therapy leads to constraints in financial resources. So, high cost of products, especially dressings such as honey-impregnated dressings and silicone dressings, is likely to restrain the market.
Opportunity:
Significant expansion of healthcare establishments
Many countries have experienced the expansion of biotechnology & pharmaceutical companies in the recent years. The extensively increasing awareness among Asian consumers regarding enhancing the quality of life has also increased. In addition to this, burden of various chronic conditions including skin cancer and breast cancer is extremely increasing in the APAC region. Thereby the consumption and constant growth of radiodermatitis in this region has increased, which can create the market opportunities for global radiodermatitis industry.
Threat:
Introduction of better radiation therapy equipment
The severity and likeliness to develop radiodermatitis can be either patient-related or treatment-related. The treatment-related factors include the type and quality of radiation beam and the location and size of the treatment field. Modern radiotherapy techniques, which include intensity-modulated radiation therapy (IMRT) and proton therapy, can diminish the risk for radiodermatitis by more accurately targeting tumor. Such scenario is expected to act as a threat to the growth of the market.
The topical segment is expected to be the largest during the forecast period
The topical segment is estimated to have a lucrative growth due to the easier application, cost-effectiveness, and its bioavailability. Topical products reduce the risk of microbial transmission and shield the skin against abrasive materials. Moreover, presence of a broad range of topical products including topical antibiotics, corticosteroids, and hydrophilic creams as well as surge in the demand for modern wound care options are some of the major factors accelerating the growth of the segment.
The online pharmacy segment is expected to have the highest CAGR during the forecast period
The online pharmacy segment is anticipated to witness the fastest CAGR growth during the forecast period owing to the various advantages such as increased convenience for patients who're unwilling to purchase medicines from retail or hospital pharmacies. Online pharmacy is an excellent platform which is playing important role in the sales of radiodermatitis medicines.
Region with highest share:
North America is projected to hold the largest market share during the forecast period due to widespread occurrence of cancer and dominant use of radiotherapy for treatment of various types of cancer. Ongoing investments in cancer research, government efforts to boost cancer awareness, and the rise in radiation therapy for cancer treatment will positively impact the regional industry dynamics.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period owing to expanding cancer patient base present across this region and extensive collaborations undertaken by key players for increasing their product portfolio expansion capabilities. Favorable government initiatives that support research activities and an increase in outsourcing by developed economies serve as key growth factors for this region.
Key players in the market
Some of the key players profiled in the Radiodermatitis Market include 3M, The Jackson Laboratory, Stratpharma AG, Smith & Nephew, Molnlycke Health Care AB, LETI Pharma, KeraNetics, Inc, KCI Licensing Inc, InterMed S.A., HARTMANN, ConvaTec, Charles River Laboratories and AceTech.
Key Developments:
In September 2019: Integra LifeSciences Holdings Corporation acquired Rebound Therapeutics. The acquisition of Rebound Therapeutics reflects Integra's ongoing commitment to developing innovative products to address unmet needs in neurosurgery.
In May 2019: 3M acquired Acelity and its KCI subsidiaries. The combination of KCI with 3M will accelerate the reach of a business that is a leader in innovation, customer experience and clinical and economic evidence.
In July 2017: Stratpharma AG launched StrataXRT®, the first and only topical film-forming wound dressing specifically designed to manage radiation dermatitis. StrataXRT is an innovative, flexible wound dressing that helps to promote a moist wound healing environment for rapid healing and faster re-epithelialization, post radiation therapy.
Products Covered:
Route of Administrations Covered:
Distribution Channels Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: